Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ORCA-010 |
Synonyms | |
Therapy Description |
ORCA-010 is an engineered oncolytic serotype 5 adenovirus (Ad5), which potentially induces enhanced cytotoxicity against tumor cells and inhibits tumor growth (PMID: 25093639, PMID: 32301504). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ORCA-010 | ORCA 010|ORCA010 | ORCA-010 is an engineered oncolytic serotype 5 adenovirus (Ad5), which potentially induces enhanced cytotoxicity against tumor cells and inhibits tumor growth (PMID: 25093639, PMID: 32301504). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04097002 | Phase Ib/II | ORCA-010 | First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | Active, not recruiting | CAN | 0 |